Abstract | BACKGROUND: METHODS: Weight was examined at baseline and 6- and 12-month follow-up in the two largest randomized, double-blind, placebo-controlled trials of naltrexone in nicotine dependence. For 6-12 weeks after the quit date, participants were randomly assigned to receive naltrexone or placebo. Behavioral counseling and open-label nicotine patch were also included for the first 4-6 weeks. Of the 700 participants in the combined intent-to-treat sample, there were 159 (77 women) biochemically verified abstinent smokers at 6 months, and 115 (57 women) of them remained abstinent at 12 months. Changes in weight (in kilograms or in percentage) and body mass index from baseline to the follow-ups were assessed for these participants. RESULTS:
Weight gain was significantly lower for women treated with naltrexone compared with placebo (6 months, 3.3 vs. 5.5 kg; 12 months, 5.9 vs. 7.4 kg, respectively). Increases in body mass index and percentage body weight gain were also significantly lower in women treated with naltrexone versus placebo. These effects were not observed in men. CONCLUSION:
|
Authors | Andrea C King, Dingcai Cao, Lingjiao Zhang, Stephanie S O'Malley |
Journal | Biological psychiatry
(Biol Psychiatry)
Vol. 73
Issue 9
Pg. 924-30
(May 01 2013)
ISSN: 1873-2402 [Electronic] United States |
PMID | 23177384
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2013 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved. |
Chemical References |
|
Topics |
- Adult
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Naltrexone
(administration & dosage, pharmacology, therapeutic use)
- Sex Factors
- Smoking Cessation
(methods)
- Treatment Outcome
- Weight Gain
(drug effects)
|